InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,864.67
(
0.40%
)
US TECH 100
19,788.00
(
0.70%
)
Dow Jones
43,275.91
(
0.09%
)
Brent Oil
72.94
(
-1.65%
)
Bitcoin
68,308.64
(
1.32%
)
Post# of 253400
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120588
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: kookiekook post# 107069

Saturday, 10/23/2010 2:37:51 PM

Saturday, October 23, 2010 2:37:51 PM

Post# of 253400
ARNA—I think AGN’s large fine for off-label marketing of Botox (#msg- 53934359) will make Eisai realize that you can’t plug off-label sales numbers into your spreadsheet when deciding whether a drug like Lorcaserin is a good business proposition. If the potential indication for Lorcaserin is limited to obese diabetics, as the FDA’s CRL suggests, it will be hard for Eisai to make the numbers work even in the best-case scenarios.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up